Principles of Molecular Utility for CMS Classification in Colorectal Cancer Management.
biomarkers predictive of drug response
biomarkers predictive of prognosis
cancer risk
colorectal cancer
consensus molecular subtype
gut microbiota
immunoscore
precision medicine
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
13 May 2023
13 May 2023
Historique:
received:
21
03
2023
revised:
05
05
2023
accepted:
09
05
2023
medline:
22
6
2023
pubmed:
22
6
2023
entrez:
22
6
2023
Statut:
epublish
Résumé
Colorectal cancer (CRC) is the second cause of cancer-related deaths in both sexes globally and presents different clinical outcomes that are described by a range of genomic and epigenomic alterations. Despite the advancements in CRC screening plans and treatment strategies, the prognosis of CRC is dismal. In the last two decades, molecular biomarkers predictive of prognosis have been identified in CRC, although biomarkers predictive of treatment response are only available for specific biological drugs used in stage IV CRC. Translational clinical trials mainly based on "omic" strategies allowed a better understanding of the biological heterogeneity of CRCs. These studies were able to classify CRCs into subtypes mainly related to prognosis, recurrence risk, and, to some extent, also to treatment response. Accordingly, the comprehensive molecular characterizations of CRCs, including The Cancer Genome Atlas (TCGA) and consensus molecular subtype (CMS) classifications, were presented to improve the comprehension of the genomic and epigenomic landscapes of CRCs for a better patient management. The CMS classification obtained by the CRC subtyping consortium categorizes CRC into four consensus molecular subtypes (CMS1-4) characterized by different prognoses. In this review, we discussed the CMS classification in different settings with a focus on its relationships with precursor lesions, tumor immunophenotype, and gut microbiota, as well as on its role in predicting prognosis and/or response to pharmacological treatments, as a crucial step towards precision medicine.
Identifiants
pubmed: 37345083
pii: cancers15102746
doi: 10.3390/cancers15102746
pmc: PMC10216373
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Subventions
Organisme : Intesa San Paolo (Milan, Italy)
Organisme : Associazione Giacomo Onlus (Castiglioncello, Italy)
Références
ESMO Open. 2020 Sep;5(5):e000847
pubmed: 32967918
J Pathol. 2014 Jan;232(2):199-209
pubmed: 24122236
JAMA Oncol. 2016 Sep 1;2(9):1162-9
pubmed: 27270348
Cancer Res. 1998 Nov 15;58(22):5248-57
pubmed: 9823339
J Exp Med. 1998 Mar 2;187(5):693-702
pubmed: 9480979
Cancer Cell. 2015 Apr 13;27(4):450-61
pubmed: 25858804
Cancer Cell. 2014 Aug 11;26(2):262-72
pubmed: 25117713
Oncotarget. 2016 Oct 4;7(40):66212-66225
pubmed: 27517155
J Exp Clin Cancer Res. 2022 Mar 29;41(1):113
pubmed: 35351152
Gastroenterology. 2020 Jan;158(2):341-353
pubmed: 31394082
JCO Precis Oncol. 2018 Jun 13;2018:
pubmed: 30088816
Transl Oncol. 2018 Oct;11(5):1188-1201
pubmed: 30071442
Cancers (Basel). 2020 May 31;12(6):
pubmed: 32486365
Medicine (Baltimore). 2018 Mar;97(9):e0019
pubmed: 29489646
Cell Death Differ. 2018 Mar;25(3):616-633
pubmed: 29305587
BMC Cancer. 2019 Nov 27;19(1):1155
pubmed: 31775679
PLoS Med. 2013;10(5):e1001453
pubmed: 23700391
Clin Cancer Res. 2012 Nov 1;18(21):6001-10
pubmed: 22991413
Nat Med. 2015 Nov;21(11):1350-6
pubmed: 26457759
Ann Oncol. 2018 Oct 1;29(10):2061-2067
pubmed: 30412224
Lancet. 2018 May 26;391(10135):2128-2139
pubmed: 29754777
Nat Rev Immunol. 2018 Jan 30;18(2):87-88
pubmed: 29379189
J Clin Oncol. 2011 Jan 1;29(1):17-24
pubmed: 21098318
JGH Open. 2019 Feb 08;3(5):361-369
pubmed: 31633039
Science. 2006 Sep 29;313(5795):1960-4
pubmed: 17008531
Virchows Arch. 2016 Aug;469(2):125-34
pubmed: 27325016
Clin Transl Gastroenterol. 2016 Mar 10;7:e151
pubmed: 26963001
Oncotarget. 2018 Apr 10;9(27):18698-18711
pubmed: 29721154
J Immunol. 1987 Jun 1;138(11):3873-6
pubmed: 2953792
Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8681-6
pubmed: 10411935
Gut. 2016 Dec;65(12):1973-1980
pubmed: 26311717
Curr Colorectal Cancer Rep. 2016;12:141-150
pubmed: 27340376
J Pathol. 2018 May;245(1):19-28
pubmed: 29412457
Clin Cancer Res. 2018 Jan 1;24(1):224-233
pubmed: 29061646
Cancer Treat Rev. 2019 May;75:1-11
pubmed: 30849607
Nucleic Acids Res. 2016 May 5;44(8):3865-77
pubmed: 26921406
Am J Surg. 2016 Oct;212(4):700-714
pubmed: 27637150
J Clin Oncol. 2019 Aug 1;37(22):1876-1885
pubmed: 31042420
Ann Surg Oncol. 2018 Jun;25(6):1454-1455
pubmed: 29616422
Sci Rep. 2017 Nov 30;7(1):16618
pubmed: 29192179
Ann Oncol. 2018 Nov 1;29(11):2240-2246
pubmed: 30247524
J Pathol. 2018 Nov;246(3):266-276
pubmed: 29968252
Front Immunol. 2020 Mar 06;11:369
pubmed: 32210966
J Clin Oncol. 2010 Jul 1;28(19):3191-8
pubmed: 20516443
Clin Colorectal Cancer. 2021 Mar;20(1):84-95.e8
pubmed: 33041226
Ther Adv Med Oncol. 2020 Jul 24;12:1758835920936089
pubmed: 32782486
Cancer. 2012 Nov 1;118(21):5234-44
pubmed: 22605513
Curr Opin Immunol. 2013 Apr;25(2):261-7
pubmed: 23579076
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
JAMA Oncol. 2017 Jul 01;3(7):921-927
pubmed: 28125762
Nat Genet. 2015 Apr;47(4):320-9
pubmed: 25706628
Int J Mol Sci. 2020 Dec 24;22(1):
pubmed: 33374459
Ann Oncol. 2019 Nov 1;30(11):1796-1803
pubmed: 31868905
Clin Colorectal Cancer. 2015 Mar;14(1):1-10
pubmed: 25579803
Eur J Cancer. 2017 May;76:68-75
pubmed: 28284171
Int J Cancer. 2014 Feb 1;134(3):552-62
pubmed: 23852808
PLoS One. 2014 Aug 13;9(8):e103207
pubmed: 25119138
Eur J Cancer. 2019 Dec;123:118-129
pubmed: 31678770
Oncogenesis. 2020 Jul 9;9(7):66
pubmed: 32647253
Oncogene. 2016 Nov 17;35(46):6026-6037
pubmed: 27157610
Arch Med Res. 2020 Nov;51(8):839-844
pubmed: 32962865
Adv Sci (Weinh). 2022 Nov;9(31):e2204097
pubmed: 36058001
Ann Oncol. 2018 May 1;29(5):1227-1234
pubmed: 29518181
Oncogene. 2020 Jun;39(26):4925-4943
pubmed: 32514151
Br J Cancer. 2019 Oct;121(7):593-599
pubmed: 31474758
Cancer Discov. 2015 Jan;5(1):43-51
pubmed: 25358689
Nat Commun. 2017 May 31;8:15107
pubmed: 28561063
Gastroenterology. 2021 Aug;161(2):592-607
pubmed: 33930428
Cancer Metastasis Rev. 2018 Mar;37(1):173-187
pubmed: 29322354
Ann Oncol. 2019 Oct 1;30(10):1622-1629
pubmed: 31504112
Oncotarget. 2017 Oct 27;8(62):105299-105311
pubmed: 29285252
Oncologist. 2015 Feb;20(2):127-33
pubmed: 25561511
Cancers (Basel). 2022 Oct 11;14(20):
pubmed: 36291761
Immunity. 2018 Apr 17;48(4):812-830.e14
pubmed: 29628290
Nat Med. 2013 May;19(5):614-8
pubmed: 23584090
Annu Rev Pathol. 2011;6:479-507
pubmed: 21090969
Br J Surg. 2018 Jan;105(2):e204-e211
pubmed: 29341165
J Exp Med. 2019 Mar 4;216(3):704-720
pubmed: 30792186
Clin Cancer Res. 2014 Apr 1;20(7):1891-9
pubmed: 24691640
BMC Cancer. 2010 Dec 23;10:691
pubmed: 21176237
Nat Rev Clin Oncol. 2011 Mar;8(3):131-3
pubmed: 21304502
J Clin Med. 2020 Nov 30;9(12):
pubmed: 33265959
Br J Cancer. 2022 Jun;126(12):1824-1833
pubmed: 35194192
N Engl J Med. 1988 Sep 1;319(9):525-32
pubmed: 2841597
Front Oncol. 2019 Jul 03;9:566
pubmed: 31334107
Int J Mol Med. 2021 Mar;47(3):
pubmed: 33655327
J Am Coll Surg. 2014 Nov;219(5):1056-69
pubmed: 25440029
Front Immunol. 2019 Feb 08;10:168
pubmed: 30800125
Nat Rev Cancer. 2012 Mar 15;12(4):298-306
pubmed: 22419253
Cancer Epidemiol Biomarkers Prev. 2019 Oct;28(10):1720-1724
pubmed: 31375479
J Exp Med. 2010 Mar 15;207(3):637-50
pubmed: 20156971
J Natl Cancer Inst. 2022 Apr 11;114(4):503-516
pubmed: 34077519
Nat Microbiol. 2019 Dec;4(12):2319-2330
pubmed: 31501538
Nature. 2015 Apr 30;520(7549):692-6
pubmed: 25901682
Gut. 2012 Nov;61(11):1560-7
pubmed: 22213796
Cancer Res. 2001 Aug 15;61(16):6046-9
pubmed: 11507051
Clin Transl Gastroenterol. 2016 Nov 3;7(11):e200
pubmed: 27811909
Ann Oncol. 2016 Aug;27(8):1386-422
pubmed: 27380959
Mol Cancer. 2017 Jul 6;16(1):116
pubmed: 28683746
Clin Cancer Res. 2016 Aug 15;22(16):4095-104
pubmed: 27151745
Mod Pathol. 2020 Dec;33(12):2626-2636
pubmed: 32581367
Sci Rep. 2017 Sep 14;7(1):11590
pubmed: 28912574
Clin Cancer Res. 2018 Feb 15;24(4):794-806
pubmed: 29242316
Cells. 2021 Mar 15;10(3):
pubmed: 33804045
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Semin Cancer Biol. 2019 Apr;55:37-52
pubmed: 29775690
Ann Surg. 2013 Jun;257(6):1053-8
pubmed: 23295318
Gastroenterology. 2023 Jul;165(1):104-120
pubmed: 36933623
J Exp Clin Cancer Res. 2020 Sep 29;39(1):202
pubmed: 32993749
Cell Host Microbe. 2018 Feb 14;23(2):203-214.e5
pubmed: 29398651
CA Cancer J Clin. 2020 May;70(3):145-164
pubmed: 32133645
Sci Rep. 2021 Apr 12;11(1):7940
pubmed: 33846436
Clin Transl Oncol. 2019 Jan;21(1):46-54
pubmed: 30565083
Clin Cancer Res. 2016 Aug 15;22(16):4057-66
pubmed: 26994146
Cancers (Basel). 2022 Oct 22;14(21):
pubmed: 36358609
EMBO Mol Med. 2016 Jul 01;8(7):745-60
pubmed: 27221051
Curr Colorectal Cancer Rep. 2012 Sep;8(3):225-231
pubmed: 23002390
Sci Rep. 2019 May 21;9(1):7665
pubmed: 31113981
Scand J Gastroenterol. 2014 Oct;49(10):1153-63
pubmed: 25144865
Eur J Cancer. 2022 Jul;169:198-209
pubmed: 35636041
Cancers (Basel). 2018 Aug 08;10(8):
pubmed: 30096811